News/ News/ Oncology BMS finally gets FDA OK for liso-cel, sets $410k launch price Phil Taylor Breyanzi, Bristol-Myers Squibb, Celgene, cell therapy, DLBCL, immuno-oncology, liso-cel, non-Hodgkin lymphoma, Oncology, TG Therapeutics, Ukoniq 0 Comment Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US Share X BMS finally gets FDA OK for liso-cel, sets $410k launch price https://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/